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        decrease in opioid prescriptions 
from 244.5M in 2014 to 153.7M in 20191
The nation’s continuing increase in drug overdoses is fueling 
the evolution of a more dangerous and complicated epidemic.
In 2014, the American Medical Association convened the AMA Opioid Task Force—more than 25 national, 
specialty and state medical associations committed to providing evidence-based recommendations and 
leadership to help end the opioid epidemic.
To date, the task force’s recommendations have led to significant progress: 
Despite these efforts, illicitly manufactured fentanyl, fentanyl analogues and stimulants (e.g. methamphet-
amine, cocaine) are now killing more Americans than ever. The use of these illicit drugs has surged and their 













































Synthetic Opioids Stimulants Heroin Prescription Opioids
37.1%         increase in the use of state  
prescription drug monitoring programs 
in the past year—to 739M queries in 20193
 naloxone prescriptions in 2019 
—up from 6,588 in 20152
64.4%
1M+
Hundreds of thousands of physicians  
accessing continuing medical education  
and other courses on substance use disorders,  
treating and managing pain, and more
85,000+ physicians and health care  
professionals certified to prescribe buprenor-


























































There are hopeful signs that overdoses related to prescription opioids are decreasing slightly. However, the 
number of drug overdoses will continue to rise unless more is done to help the more than 2 million Americans 
with an untreated substance use disorder.
Research shows that people who have had at least one overdose are more likely to have another.⁵  
Removing the barriers for patients to receive evidence-based treatment is a critical first step to helping  
end the epidemic.





Data not available/not reported
This transformation has rapidly changed the opioid epidemic  
into a more complicated drug overdose epidemic.
Change in non-fatal drug overdoses (January 2019–January 2020)
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Policymakers need to act to remove  
barriers to evidence-based care for  
patients with pain and those with  
a substance use disorder or the  
epidemic will continue to worsen.
Health insurance companies continue to delay and deny access to non-opioid pain care and evidence-based 
treatment for opioid use disorder, while pharmacy chains, pharmacy benefit managers and state laws continue 
to inappropriately use arbitrary guidelines to restrict access to legitimate medication that some patients need 
to help manage their pain.
•  92% of pain medicine specialists said that they 
have been required to submit a prior  
authorization request for non-opioid pain care. 
Physicians and their staff spend hours  
per day on such requests.⁶ 
•  72% of pain medicine specialists said that 
they—or their patients—have been required to 
reduce the quantity or dose of medication they 
have prescribed.⁷
Mental health and substance use disorder parity laws require health insurers to provide the same level of benefits 
for mental health and substance use disorder treatment and services that they do for medical/surgical care. 
However, only a few states (e.g., Arizona, California, Colorado, Delaware, Illinois, Massachusetts, Pennsylvania, 
Rhode Island) have taken meaningful action to enact or enforce those laws.
In 2019, the AMA partnered with Manatt Health to publish a state policy roadmap to provide tangible actions for 
policymakers to take meaningful action on parity and other areas necessary to end the epidemic. 
Only 21 states and the District of Columbia have 
enacted laws that limit public and/or private  
insurers from imposing prior authorization  
requirements on a [substance use disorder] 
service or medication.⁸ The AMA helped support 
passage of more than one dozen of those laws 
in 2019 alone. Health plans fight bitterly to 
oppose these laws.
Landmark ruling sets precedent for parity  
coverage of mental health and addiction  
treatment                  –Stat News
Every lawmaker in Arizona just voted for better 
mental health care. That’s a big deal    –AZ Central
Report: Health insurers biased in treating mental-health
–Providence Journal
AG Healey reaches $1 million settlement  
with 7 companies to increase behavioral  
health access                   –WBUR
PA: Aetna violated parity laws in substance abuse coverage 
 –Bucks County Courier Times





Evolve to prevention 
framework
 Prioritize preventing  
and treating substance 
use disorders
Employ effective  
surveillance strategies
Better identify patients  
at risk of an overdose and 
those who have over-
dosed in the past
Implement proven  
public health solutions
Take an evidence-based 
approach to prevention 
and treatment
Treating the nation’s drug overdose
epidemic demands a far more proactive
and coordinated approach focused
on evidence-based, public health solutions.
To date, efforts to combat the epidemic have largely fallen into a reactionary 
 “crisis framework,” which has created too many one-size-fits-all strategies  
that are less than effective. Going forward, physicians, public health officials, 
policymakers and health insurance companies must work together to create 
an integrated, sustainable, predictable and resilient public health system.
Improving the collection and use of data is critical to evolving the nation’s efforts to combat the epidemic. 
For example, currently, overdose-related data collection practices are not consistent across the United 
States. Modernizing and adapting data collection will allow stakeholders to develop more effective  
solutions tailored to the needs of individuals and their community. 
Policies and treatments must consider 
that patients are not identical.  
They must account for drug type,  
gender, race, age and social  
determinants of health.
The nature of the epidemic and its 
evolution are not the same across the 
country. They are not even the same 
within a state. Their solutions must 
be equally as varied.
What we do today:   
“Crisis framework”
What we must do tomorrow:  
Integrated, sustainable, predictable and resilient public health system
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Remove prior authorization, step therapy and  
other inappropriate administrative burdens or  
barriers that delay or deny care for FDA-approved  
medications used as part of medication-assisted  
treatment for opioid use disorder.
Support assessment, referral and treatment for  
co-occurring mental health disorders as well as  
enforce meaningful oversight and enforcement  
of state and federal mental health and substance  
use disorder parity laws, including requiring health  
insurance companies to demonstrate parity  
compliance at the time of their rate and form filing. 
Remove administrative and other barriers to comprehensive, multi-modal, multidisciplinary pain  
care and rehabilitation programs.
Support maternal and child health by 
increasing access to evidence-based 
treatment, preserving families and 
ensuring that policies are non- 
punitive. 
Support increased efforts to expand 
sterile needle and syringe services 
programs as well as reforms in the 
civil and criminal justice system that 
help ensure access to high quality, 
evidence-based care for opioid use 
disorder, including medication- 
assisted treatment.
Implement systems to accurately track overdose and mortality trends to provide equitable public health 
interventions that include comprehensive, disaggregated, racial and ethnic data collection related to  
testing, hospitalization and mortality associated with opioids and other substances.
The AMA urges policymakers 
and other stakeholders to take 
meaningful action to remove 
barriers and increase patients’ 
access to evidence-based care 
to save lives and help end the 
epidemic.
Physicians’ progress alone will not end the  
epidemic. Policymakers, health insurance
companies, pharmacy chains and others must
move beyond words; they must take meaningful
action to remove barriers to evidence-based
care. We all need to work together, but the
status quo is killing far too many of our loved
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More stakeholders must come together and work  
collaboratively to act on these recommendations.
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– Patrice A. Harris, MD, MA  
Chair, AMA Opioid Task Force
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